Related Experiment Video
Updated: Jul 15, 2026
15:08
Monitoring Astrocyte Reactivity and Proliferation in Vitro Under Ischemic-Like Conditions
Published on: October 21, 2017
Aldehydic lipid peroxidation products in human brain astrocytomas
Alicja Zajdel1, Adam Wilczok, Jerzy Slowinski
1Department of Biopharmacy, Medical University of Silesia, Narcyzow 1, Sosnowiec 41-200, Poland. azajdel@slam.katowice.pl
Journal of Neuro-Oncology
|May 10, 2007
Summary
Aldehydic lipid peroxidation products and histone H3 mRNA levels can indicate malignancy in brain astrocytomas. Higher levels of specific aldehydes correlate with poorer prognosis, aiding in treatment selection.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Oxidative stress generates reactive aldehydes from lipid peroxidation, implicated in mutagenesis and carcinogenesis.
- These aldehydes may also function as growth regulators and signaling molecules.
- Biomarkers are needed for astrocytoma grading and prognosis.
Purpose of the Study:
- To investigate aldehydic lipid peroxidation products and histone H3 mRNA as biomarkers for malignancy in human brain astrocytomas.
- To assess their potential as predictive factors for patient outcomes.
Main Methods:
- Analysis of histone H3 mRNA using quantitative reverse transcription polymerase chain reaction (QRT-PCR).
- Quantification of aldehydic lipid peroxidation products (as dinitrophenylhydrazone derivatives) using RP-HPLC with diode array detection and MSMS spectrometry.
- Study included specimens from 26 adult patients with brain astrocytomas.
Main Results:
- Histone H3 mRNA, 2-hydroxyhexanal, and 4-hydroxynonenal levels were elevated in high-grade astrocytomas compared to low-grade ones.
- Elevated levels of these markers showed a negative correlation with patient survival.
- Higher 2-hydroxyhexanal and 4-hydroxynonenal, and lower n-hexanal levels were linked to poorer prognosis.
Conclusions:
- Tissue concentrations of aldehydic lipid peroxidation products may aid in grading astrocytic brain tumors.
- These markers show potential for predicting clinical outcomes in astrocytoma patients.
- This parameter could facilitate personalized treatment strategies based on tumor profiles.
